Curaleaf Hits $340M In Q2 Sales; Cannabis Giant Pushes Toward Global Leadership

Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) reported on Wednesday that its second-quarter revenue hit $340.1 million. That’s an increase of 10% year-over-year and 5% sequentially.

The cannabis giant revealed domestic revenue grew 7% year-over-year, marking the second consecutive quarter of year-over-year domestic growth. International revenue grew 26% over the same period.

“Our second quarter results reinforce that our ‘Built for Growth’ strategy, a disciplined framework focused on customer centricity, brand building, and operational excellence, is gaining traction across the business,” Chairman and CEO Boris Jordan said in a press release. “We have a strong, cohesive team aligned around one common goal: making Curaleaf the global leader in cannabis.”

Other quarterly business highlights include expansion of Curaleaf’s Florida retail presence to 73 dispensaries and wrapping up the acquisition of the remaining 45% stake in Four20 Pharma, making Curaleaf International, which has a presence in 16 countries across Europe, Australasia and North America, 100% owned.

In addition, Curaleaf applied to register all medical cultivation, processing and dispensing locations with the DEA.

Q2 2026 Financial Highlights

• Gross profit totaled $169.9 million, with a gross profit margin of 50%, representing an increase of 70 basis points year-over-year.
• Net income from continuing operations was $12.5 million, or $0.05 per share.
• Adjusted EBITDA came in positive at $70.1 million, while the adjusted EBITDA margin was 20.6%, a 120-basis-point decrease year-over-year.
• Total cash and cash equivalents at quarter-end amounted to $107 million.

CURLF Price Action

Curaleaf’s shares traded 8.10% lower at $8.28 per share as of Wednesday.